SCIENTIFIC BACKGROUND

ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, B4GALT1, CAD, CCDC115, COG1, COG4, COG5, COG6, COG7, COG8, DDOST, DOLK, DPAGT1, DPM1, DPM2, DPM3, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PMM2, RFT1, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SRD5A3, SSR4, STT3A, STT3B, TMEM165, TMEM199, TUSC3

Scientific Background

Congenital disorders of glycosylation (CDG syndrome) are hereditary defects of glycoprotein biosynthesis and are genetic metabolic defects. They are usually severe multi-organ diseases with often pronounced neurological disorders. Various subtypes of CDG syndrome are known, which have been grouped according to the location of the respective defect within the cell and not according to clinical aspects. NGS panel diagnostics can currently examine 43 genes for different CDG types.

 

The most common is CDG syndrome type Ia, which is caused by a phosphomannomutase deficiency due to mutations in the PMM2 gene. A pronounced developmental disorder is typical; brain malformations, skeletal anomalies, inverted nipples, coagulation defects and other symptoms may also occur. The suspected diagnosis is usually assessed first using metabolic diagnosis to detect abnormal glycosylation of serum glycoproteins by serum transferrin electrophoresis, and then confirmed by molecular genetic examination. However, evidence of abnormal glycosylation of serum glycoproteins is not present in all types of CDG syndrome. Therefore, if the serum transferrin electrophoresis is inconspicuous and the suspected diagnosis remains, NGS panel diagnostics may be indicated and may lead to a diagnosis in individual cases and thus to more precise statements on the prognosis and the risk of recurrence.

 

References

Gilfix B.M. 2019, Hum Mutat. 40:1010 / Francisco et al. 2019, J Inherit Metab Dis. 42:29 / Francisco et al. 2019, Mol Genet Metab. 126:1 / van Tol et al. 2019, Curr Opin Struct Biol. 56:107 / Chang et al. 2018, Ann Transl Med. 6:477

GENES

ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, B4GALT1, CAD, CCDC115, COG1, COG4, COG5, COG6, COG7, COG8, DDOST, DOLK, DPAGT1, DPM1, DPM2, DPM3, MGAT2, MOGS, MPDU1, MPI, NGLY1, PGM1, PMM2, RFT1, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SRD5A3, SSR4, STT3A, STT3B, TMEM165, TMEM199, TUSC3
How to order

LATEST ARTICLES

Traditional DNA tests may overlook 10% of classic in Familial Adenomatous Polyposis (FAP) cases. By integrating RNA sequencing, researchers unveiled ...

Read more

Overview In January 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published new recommendation...

Read more

Endometriosis is a chronic gynecological condition that affects 1 in 10 women of reproductive age worldwide [1]. It can manifest with the first menst...

Read more

Rare Disease Day is a global awareness day held annually to raise awareness of all rare diseases. It was first celebrated in 2008, on the rarest day ...

Read more

Cancer is a group of genetic diseases that can develop almost anywhere in the body. Many people in the world are affected by cancer every year. Follo...

Read more

Aiming to evaluate the role of chromosomal aneuploidy in pregnancy loss, a 2023 study 35 years in the making evaluated the genomic landscape of first...

Read more

Cancer is a complex genetic disease that affects millions of people in the world. It is one of the leading causes of death worldwide, with about ten ...

Read more

Researchers created a detailed map of the placenta during labor. By studying how maternal and fetal cells communicate, they discovered signals in the...

Read more

A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized the...

Read more

In honor of the international day of women and girls in science, we interviewed one of our very own, Dr. Evelina Papaioannou. Dr. Evelina Pa...

Read more